Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors
July 30 2020 - 4:05PM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,”
or “we”), a clinical-stage biopharmaceutical company, today
announced the appointment of Martin W. Edwards, M.D. to its Board
of Directors, effective August 3, 2020.
Since 2003, Dr. Edwards has held various
positions at Novo Holdings, a life sciences investment firm, and
most recently, he has served as a part-time Senior Partner.
Earlier in his career, he was Corporate VP and Global Head of
Drug Development for Novo Nordisk, where he led all aspects of
pre-clinical and clinical drug development. Dr. Edwards
currently serves on the board of directors of three publicly traded
pharmaceutical companies, Inozyme Pharma, Inc., Kalvista
Pharmaceuticals, Inc., and Verona Pharma plc. He previously
served on the board of directors of CoLucid Pharmaceuticals, Inc.,
which was a publicly traded pharmaceutical company. Dr.
Edwards trained in physiology and medicine at the University of
Manchester, where he obtained his M.D. He is a Member of the
Royal College of Physicians, a Member with distinction of the Royal
College of General Practitioners, a Fellow of the Faculty of
Pharmaceutical Medicine, and holds an M.B.A. from the University of
Warwick.
“I’m honored to join Reata’s Board, and I look
forward to the opportunity to help oversee the Company’s important
work,” said Dr. Edwards. “I’m excited to be part of realizing
Reata’s mission to improve the lives of people facing serious and
life-threatening diseases.”
“I’m very pleased to welcome Dr. Edwards to
Reata’s Board,” said Warren Huff, Reata’s Chairman, Chief Executive
Officer and President. “He is a highly respected leader in
our industry, with valuable experience across many organizations
and therapeutic areas. Our Board and Company will benefit
from his insights and counsel as Reata continues to make progress
toward becoming a fully integrated, global, commercial
enterprise.”
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone
methyl (“bardoxolone”) and omaveloxolone, target the important
transcription factor Nrf2 that promotes the resolution of
inflammation by restoring mitochondrial function, reducing
oxidative stress, and inhibiting pro-inflammatory signaling.
Bardoxolone and omaveloxolone are investigational
drugs, and their safety and efficacy have not been established by
any agency.
Contact:Reata Pharmaceuticals, Inc.(972)
865-2219http://reatapharma.com
Investors:Vinny JindalVice President, Corporate
Communications and Strategy(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, our
plans to submit regulatory filings, and our ability to obtain and
retain regulatory approval of our product candidates. You can
identify forward-looking statements because they contain words such
as “believes,” “will,” “may,” “aims,” “plans,” “model,” and
“expects.” Forward-looking statements are based on Reata’s
current expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks, and changes in circumstances that may differ
materially from those contemplated by the forward-looking
statements, which are neither statements of historical fact nor
guarantees or assurances of future performance. Important
factors that could cause actual results to differ materially from
those in the forward-looking statements include, but are not
limited to, (i) the timing, costs, conduct, and outcome of our
clinical trials and future preclinical studies and clinical trials,
including the timing of the initiation and availability of data
from such trials; (ii) the timing and likelihood of regulatory
filings and approvals for our product candidates; (iii) whether
regulatory authorities determine that additional trials or data are
necessary in order to obtain approval; (iv) the potential market
size and the size of the patient populations for our product
candidates, if approved for commercial use, and the market
opportunities for our product candidates; and (v) other factors set
forth in Reata’s filings with the U.S. Securities and Exchange
Commission, including the detailed factors discussed under the
caption “Risk Factors” in its Annual Report on Form 10-K for the
fiscal year ended December 31, 2019. The forward-looking
statements speak only as of the date made and, other than as
required by law, we undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024